Routine EGFR and KRAS mutation analysis using COLD-PCR in non-small cell lung cancer

International Journal of Clinical Practice

Volumn 66, Issue 8, 2012, Pages 748-752

  Pennycuick, A ^a   Simpson, T ^b   Crawley, D ^a,b   Lal, R ^b   Santis, G ^a,b   Cane, P ^b   Tobal, K ^b   Spicer, J ^a,b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; K RAS PROTEIN;

ADULT; AGED; ARTICLE; COLD POLYMERASE CHAIN REACTION; DEMOGRAPHY; EPIDERMAL GROWTH FACTOR RECEPTOR GENE; EXON; FEMALE; GENE AMPLIFICATION; GENE MUTATION; GENE SEQUENCE; HUMAN; KRAS GENE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL;

EID: 84863954773     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2012.02961.x     Document Type: Article

References (23)

1. Mok TS, Wu YL, Thongprasert S, et al., Gefitinib or carboplatin- paclitaxel in pulmonary adenocarcinoma. New England J Med 2009; 361: 947-57.
2. Rosell R, Gervais R, Vergnenegre A, et al., Erlotinib versus chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations: Interim results of the European Erlotinib Versus Chemotherapy (EURTAC) phase III randomized trial. J Clin Oncol 2011; 29: suppl; abstract 7503.
3. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al., Erlotinib in previously treated non-small-cell lung cancer. New England J Med 2005; 353: 123-32. (Pubitemid 41058344)
4. Pao W, Wang TY, Riely GJ, et al., KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2005; 2: e17.
5. Kosaka T, Yatabe Y, Endoh H, et al., Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res 2004; 64: 8919-23. (Pubitemid 39665498)
6. Shigematsu H, Lin L, Takahashi T, et al., Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J National Cancer Inst 2005; 97: 339-46. (Pubitemid 40425952)
7. Shigematsu H, Gazdar AF,. Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. Inter J cancer J Inter du Cancer 2006; 118: 257-62. (Pubitemid 41779062)
8. Santis G, Angell R, Nickless G, et al., Screening for EGFR and KRAS mutations in endobronchial ultrasound derived transbronchial needle aspirates in non-small cell lung cancer using COLD-PCR. PLoS ONE 2011; 6: e25191.
9. Riely GJ, Marks J, Pao W,. KRAS mutations in non-small cell lung cancer. Proc Am Thoracic Soc 2009; 6: 201-5.
10. Li J, Wang L, Mamon H, et al., Replacing PCR with COLD-PCR enriches variant DNA sequences and redefines the sensitivity of genetic testing. Nat Med 2008; 14: 579-84. (Pubitemid 351655208)
11. Maheswaran S, Sequist LV, Nagrath S, et al., Detection of mutations in EGFR in circulating lung-cancer cells. New England J Med 2008; 359: 366-77.
12. Somatic Mutations in Epidermal Growth Factor Receptor DataBase. 2008 [cited 5 December 2011]; Available from
13. Catalogue Of Somatic Mutations in Cancer (COSMIC) v56. 2011 15 November 2011 [cited 5 December 2011 ]; v56:[Available from
14. Sahoo R, Harini VV, Babu VC, et al., Screening for EGFR mutations in lung cancer, a report from India. Lung Cancer 2011; 73: 316-9.
15. Dowell JE, Minna JD,. EGFR mutations and molecularly targeted therapy: a new era in the treatment of lung cancer. Nat Clin Pract Oncol 2006; 3: 170-1.
16. Laurent-Puig P, Lievre A, Blons H,. Mutations and response to epidermal growth factor receptor inhibitors. Clin Cancer Res Official J Am Assoc Cancer Res 2009; 15: 1133-9.
17. Murray S, Dahabreh IJ, Linardou H, et al., Somatic mutations of the tyrosine kinase domain of epidermal growth factor receptor and tyrosine kinase inhibitor response to TKIs in non-small cell lung cancer: an analytical database. J Thoracic Oncol Official Public Inter Assoc Study Lung Cancer 2008; 3: 832-9.
18. Wu JY, Wu SG, Yang CH, et al., Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response. Clin Cancer Res Official J Am Assoc Cancer Res 2008; 14: 4877-82.
19. Brugger W, Triller N, Blasinska-Morawiec M, et al., Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer. J Clin Oncol Official J Am Soc Clin Oncol 2011; 29: 4113-20.
20. Douillard JY, Shepherd FA, Hirsh V, et al., Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial. J Clin Oncol Official J Am Soc Clin Oncol 2010; 28: 744-52.
21. Zhu CQ, da Cunha Santos G, Ding K, et al., Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol Official J Am Soc Clin Oncol 2008; 26: 4268-75.
22. Roberts PJ, Stinchcombe TE, Der CJ, Socinski MA,. Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy? J Clin Oncol Official J Am Soc Clin Oncol 2010; 28: 4769-77.
23. Gazdar AF, Shigematsu H, Herz J, Minna JD,. Mutations and addiction to EGFR: the Achilles 'heal' of lung cancers? Trends Mole Med 2004; 10: 481-6. (Pubitemid 39303620)